Send to

Choose Destination
See comment in PubMed Commons below
Clin Interv Aging. 2013;8:191-200. doi: 10.2147/CIA.S30729. Epub 2013 Feb 15.

A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly.

Author information

  • 1Gastroenterology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.


Chronic constipation is a common disorder in the general population, with higher prevalence in the elderly, and is associated with worse quality of life and with greater health care utilization. Lubiprostone is an intestinal type-2 chloride channel activator that increases intestinal fluid secretion, small intestinal transit, and stool passage. Lubiprostone is currently approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation and of irritable bowel syndrome with predominant constipation. This review outlines current approaches and limitations in the treatment of chronic constipation in the elderly and discusses the results, limitations, and applicability of randomized, controlled trials of lubiprostone that have been conducted in the general and elderly population, with additional focus on the use of lubiprostone in constipation in Parkinson's disease and in opioid-induced constipation, two clinical entities that can be comorbid in elderly patients.


Parkinson’s disease; chronic constipation; irritable bowel syndrome; opioid-induced constipation

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center